XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue - I-Mab Biopharma (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 7 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Jun. 30, 2022
Jun. 30, 2021
Jul. 31, 2022
Dec. 31, 2022
Collaboration And Other Agreements [Line Items]            
Revenues $ 24,496 $ 11,101        
Deferred revenue, current 9,249         $ 9,988
Deferred revenue, net of current portion 58,006         59,480
I-Mab | I-Mab Biopharma Collaboration and License Agreement            
Collaboration And Other Agreements [Line Items]            
Non-refundable upfront payment       $ 15,000    
Development and regulatory milestones recognized $ 5,000   $ 5,000      
Estimated variable consideration       $ 1,000    
One-time credit paid, percent 80.00%          
Revenues $ 0 200        
One Time Millstone Credit           $ 4,500
I-Mab | I-Mab Biopharma Collaboration And License Agreement Clinical Supply            
Collaboration And Other Agreements [Line Items]            
Revenues 0 900        
Incyte Corporation | RevenuesFromCMOAgreementsMember            
Collaboration And Other Agreements [Line Items]            
Non-refundable upfront payment         $ 10,000  
Revenues 3,600 $ 0        
Deferred revenue 7,800          
Deferred revenue, current 7,100          
Deferred revenue, net of current portion $ 700